A schizophrenia-related sensorimotor deficit links α3-containing GABAA receptors to a dopamine hyperfunction

Proceedings of the National Academy of Sciences of the United States of America

Volumn 102, Issue 47, 2005, Pages 17154-17159

  Yee, B K ^b   Keist, R ^a   Von Boehmer, L ^a   Studer, R ^a   Benke, D ^a   Hagenbuch, N ^b   Dong, Y ^d   Malenka, R C ^d   Fritschy, J M ^a   Bluethmann, H ^e   Feldon, J ^b   Mohler H ^a,c   Rudolph, U ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c Swiss Federal Institute of Technology Collegium Helveticum   (Switzerland)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Haloperidol; Sensorimotor gating

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA3; AMPHETAMINE DERIVATIVE; DIAZEPAM; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; ELEVATED PLUS MAZE TEST; GENE DISRUPTION; KNOCKOUT MOUSE; MAZE TEST; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PHENOTYPE; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORIMOTOR DEFICIT; STARTLE REFLEX; SYMPTOMATOLOGY; UPREGULATION; WHOLE CELL;

AMPHETAMINE; ANIMALS; ANTI-ANXIETY AGENTS; DIAZEPAM; DISEASE MODELS, ANIMAL; DOPAMINE; ELECTROPHYSIOLOGY; GABA MODULATORS; GENE TARGETING; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; ION CHANNEL GATING; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PROTEIN SUBUNITS; RECEPTORS, GABA-A; SCHIZOPHRENIA;

ANIMALIA;

EID: 28044453713     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0508752102     Document Type: Article

References (43)

1. Robbins, T. W. (2000) Exp. Brain Res. 133, 130-138.
2. Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M. & Carlsson, M. L. (2001) Annu. Rev. Pharmacol. Toxicol. 41, 237-260.
3. Fritschy, J. M. & Möhler, H. (1995) J. Comp. Neurol. 359, 154-194.
4. Roberts, E. (1972) Neurosci. Res. Program Bull. 10, 468-482.
5. Lewis, D. A., Volk, D. W. & Hashimoto, T. (2004) Psychopharmacology 174, 143-150.
6. Benes, F. M. & Berretta, S. (2001) Neuropsychopharmacology 25, 1-27.
7. Lewis, D. A., Hashimoto, T. & Volk, D. W. (2005) Nat. Rev. Neurosci. 6, 312-324.
8. Spencer, K. M., Nestor, P. G., Perlmutter, R., Niznikiewicz, M. A., Klump, M. C., Frumin, M., Shenton, M. E. & McCarley, R. W. (2004) Proc. Natl. Acad. Sci. USA 101, 17288-17293.
9. Impagnatiello, F., Guidotti, A. R., Pesold, C., Dwivedi, Y., Caruncho, H., Pisu, M. G., Uzunov, D. P., Smalheiser, N. R., Davis, J. M., Pandey, G. N., et al (1998) Proc. Natl. Acad. Sci. USA 95, 15718-15723.
10. Guidotti, A., Auta, J., Davis, J. M., Di-Giorgi-Gerevini, V., Dwivedi, Y., Grayson, D. R., Impagnatiello, F., Pandey, G., Pesold, C., Sharma, R., et al. (2000) Arch. Gen. Psychiatry 57, 1061-1069.
11. Fatemi, S. H., Earle, J. A. & McMenomy, T. (2000) Mol. Psychiatry 5, 654-663.
12. Knable, M. B., Barci, B. M., Webster, M. J., Meador-Woodruff, J. & Torrey, E. F. (2004) Mol. Psychiatry 9, 609-620.
13. Rodriguez, M. A., Caruncho, H. J., Costa, E., Pesold, C., Liu, W. S. & Guidotti, A. (2002) J. Comp. Neurol. 451, 279-288.
14. Weickert, C. S., Hyde, T. M., Lipska, B. K., Herman, M. M., Weinberger, D. R. & Kleinman, J. E. (2003) Mol. Psychiatry 8, 592-610.
15. Braff, D. L. & Geyer, M. A. (1990) Arch. Gen. Psychiatry 47, 181-188.
16. Dong, Y., Saal, D., Thomas, M., Faust, R., Bonci, A., Robinson, T. & Malenka, R. C. (2004) Proc. Natl. Acad. Sci. USA 101, 14282-14287.
17. Hauser, J., Rudolph, U., Keist, R., Möhler. H., Feidon, J. & Yee, B. K. (2005) Mol. Psychiatry 10, 201-207.
18. Lister, R. G. (1987) Psychopharmacology 92, 180-185.
19. Yee, B. K., Hauser, J., Dolgov, V. V., Keist, R., Möhler, H., Rudolph, U. & Feldon, J. (2004) Eur. J. Neurosci. 20, 1928-1936.
20. Hasty, P., Crist, M., Grompe, M. & Bradley, A. (1994) Mol. Cell. Biol. 14, 8385-8390.
21. Rudolph, U., Brabet, P., Hasty, P., Bradley, A. & Birnbaumer, L. (1993) Transgenic Res. 2, 345-355.
22. Dymecki, S. M. (1996) Proc. Natl. Acad. Sci. USA 93, 6191-6196.
23. Chrobak, J. J. & Napier, T. C. (1993) J. Neural Transm. 93, 123-143.
24. Brudzynski, S. M., Wu, M. & Mogenson, G. J. (1993) Can. J. Physiol. Pharmacol. 71, 394-406.
25. Okada, H., Matsushita, N. & Kobayashi, K. (2004) J. Neurochem. 89, 7-14.
26. Low, K., Crestani, F., Keist, R., Benke, D., Brunig, I., Benson, J. A., Fritschy, J. M., Rulicke, T., Bluethmann, H., Möhler, H. & Rudolph, U. (2000) Science 290, 131-134.
27. Rudolph, U., Crestani, F., Benke, D., Brunig, I., Benson, J. A., Fritschy, J. M., Martin, J. R., Bluethmann, H. & Möhler, H. (1999) Nature 401, 796-800.
28. McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) Nat. Neurosci. 3, 587-592.
29. Crestani, F., Keist, R., Fritschy, J. M., Benke, D., Vogt, K., Prut, L., Bluthmann, H., Möhler, H. & Rudolph, U. (2002) Proc. Natl. Acad. Sci. USA 99, 8980-8985.
30. Lisman, J. E. & Grace, A. A. (2005) Neuron 46, 703-713.
31. Russig, H., Spooren, W., Durkin, S., Feldon, J. & Yee, B. K. (2004) Psychopharmacology 175, 143-147.
32. Cadenhead, K. S., Geyer, M. A. & Braff, D. L. (1993) Am. J. Psychiatry 150, 1862-1867.
33. Swerdlow, N. R., Benbow, C. H., Zisook, S., Geyer, M. A. & Braff, D. L. (1993) Biol. Psychiatry 33, 298-301.
34. Swerdlow, N. R., Paulsen, J., Braff, D. L., Butters, N., Geyer, M. A. & Swenson, M. R. (1995) J. Neurol. Neurosurg. Psychiatry 58, 192-200.
35. Yee, B. K., Russig, H. & Feldon, J. (2004) Neuropsychopharmacology 29, 240-248.
36. Pirker, S., Schwarzer, C., Wieseithaler, A., Sieghart, W. & Sperk, G. (2000) Neuroscience 101, 815-850.
37. Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L. & Innis, R. (1999) Biol. Psychiatry 46, 56-72.
38. Parwani, A., Duncan, E. J., Bartlett, E., Madonick, S. H., Eiferen, T. R., Rajan, R., Sanfilipo, M., Chappell, P. B., Chakravorty, S., Gonzenbach, S., et al. (2000) Biol. Psychiatry 47, 662-669.
39. Chouinard, G., Annable, L., Turnier, L., Holobow, N. & Szkrumelak, N. (1993) Can. J. Psychiatry 38, Suppl. 4, S114-S121.
40. Lingjaerde, O. (1983) in The Benzodiazepines: From Molecular Biology to Clinical Practice, ed. Costa, E. (Raven, New York), pp. 369-381.
41. Pecknold, J. C. (1993) J. Psychiatry Neurosci. 18, 82-84.
42. Delini-Stula, A. & Berdah-Tordjman, D. (1996) J. Psychiatr. Res. 30, 239-250.
43. Ma, J., Ye, N., Lange, N. & Cohen, B. M. (2003) Neuroscience 121, 991-998.